

MARKET UPDATE
Sensex
59601.84 ↓ -621.31

TOP LOSER
Tube Investments
1803.55 ↓ -97.75

BEST EQUITY FUND
Quant Small Cap Fund(G)

1Y Return
↑ +87.31

MARKET UPDATE
Nifty
17745.90 ↓ -179.35

MORE MARKET STATS

ADVERTISEMENT

HOME / LIFESTYLE / HEALTH / Dr Reddy's To Launch Molflu At Rs 35 Per Capsule For COVID Treatment

Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment

ADVERTISEMENT

With 10 capsules per strip, the total course of 40 capsules over 5 days would cost Rs 1,400, making it among the most affordable treatment options available to patients, it added.

Written By **PTI**
January 4, 2022 5:32:08 pm



"Molflu is expected to be available from early next week in pharmacies throughout the country with particular focus on states with high caseload of COVID-19," the spokesperson noted.

Dr Reddy's Laboratories on Tuesday said it will launch Molflu (Molnupiravir) at Rs 35 per capsule to treat COVID-19 in the country. Molflu will be priced at Rs 35 per capsule, a spokesperson of the Hyderabad-based drug maker said in a statement. With 10 capsules per strip, the total course of 40 capsules over 5 days would cost Rs 1,400, making it among the most affordable treatment options available to patients, it added.

"Molflu is expected to be available from early next week in pharmacies throughout the country with particular focus on states with high caseload of COVID-19," the spokesperson noted. Last year, Dr Reddy's entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).

In a first-of-its-kind collaboration in the Indian pharmaceutical industry, a Dr Reddy's-led consortium of pharma companies collaborated to jointly sponsor, supervise and monitor the Phase III clinical trial of Molnupiravir in India, and presented its findings to the Subject Expert Committee.

US Stock Market

January Barometer sets the tone for Wall Street returns in 2022



3 US ETFs to invest abroad as S&P 500, Nasdaq 100 surge 27%, Dow 30 clocks 19% in 2021



US-listed cruise stocks fall as CDC issues warning amid Omicron scare; Royal Caribbean, Carnival, others tank



Warren Buffett's top stocks: Apple, Bank of America, others zoom 50% this year; which ones do you own?



S&P 500 gets 69th record close for 2021 as momentum continues in US stocks



VIEW ALL →

ADVERTISEMENT

Last week, Dr Reddy's received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market oral antiviral drug Molnupiravir capsules 200 mg for the treatment of adult patients with COVID-19 who have high risk of progression of the disease including hospitalisation or death. Molflu will be manufactured at a USFDA-approved facility, and the drug maker has made adequate capacity preparations to ensure that it is able to help patients in need, it said.

Get live [Stock Prices](#) from [BSE](#), [NSE](#), [US Market](#) and latest NAV, portfolio of [Mutual Funds](#), Check out latest [IPO News](#), [Best Performing IPOs](#), calculate your tax by [Income Tax Calculator](#), know market's [Top Gainers](#), [Top Losers](#) & [Best Equity Funds](#). Like us on [Facebook](#) and follow us on [Twitter](#).

 Financial Express is now on Telegram. [Click here to join our channel](#) and stay updated with the latest Biz news and updates.

NEXT STORY ►

Conditions hard for 13 million under China virus lockdown



NSE **BSE** **US Stocks**

AS ON

:

1d 1w 1m 3m 6m 1yr 3yr

[VIEW ALL MARKET DATA](#)

Latest News

NCLAT order: Vedanta's bid for Videocon rejected



Udaan bags funding worth \$200 million



Arbitration stayed: Big relief for Future in feud with Amazon



Buying a house becomes most affordable in a decade



Voter ID-Aadhaar linking a good idea



OECD's Model Rules: From the drawing board to reality



Consider needs while launching courses...



ADVERTISEMENT

Most Read

Airtel, Hughes form JV for satellite broadband



Xiaomi India evaded customs duty of Rs 653 crore: Finance ministry



Delhi HC stays TDSAT order on mobile number portability



Tur dal imports at a new high; retail prices stabilise



Photos



8 PHOTOS

OnePlus 10 Pro first look in pictures: Design, specs, features, and everything to know